Insider · SEC Form 4 filer
Hongbo Lu
Past buys: 1 of 4 beat
Companies
Where they file as an insider
Arrowhead Pharmaceuticals (ARWR) Director Latest filing May 12, 2026
Zenas BioPharma (ZBIO) Director Latest filing Mar 31, 2026
Terns Pharmaceuticals (TERN) Director Latest filing Sep 12, 2024
Track record
Did their buys beat the typical stock?
Open-market buys10
Quarters checked 6 months later4
Beat the typical stock 1 of 4
Quarters too new to check0
1 of 4 checked quarters beat the typical stock. A past record is data, not a forecast.
Zenas BioPharma (ZBIO) Bought Feb 11–Mar 31, 2026 · $2.15M · 104,753 shares Beat typical Mar 31, 2026 $19.55 → Sep 30, 2026 $26.97 · +38.0% (typical stock +1.7%)
Zenas BioPharma (ZBIO) Bought Oct 7, 2025 · $5M · 263,160 shares Behind typical Dec 31, 2025 $36.31 → Jun 30, 2026 $25.38 · −30.1% (typical stock +4.7%)
Zenas BioPharma (ZBIO) Bought Sep 13, 2024 · $1000K · 58,823 shares Behind typical Sep 30, 2024 $16.92 → Mar 31, 2025 $7.90 · −53.3% (typical stock −7.5%)
Terns Pharmaceuticals (TERN) Bought Sep 12, 2024 · $5M · 476,190 shares Not counted Not counted. We have no fund price for this stock on both Sep 30, 2024 and Mar 31, 2025.
Arrowhead Pharmaceuticals (ARWR) Bought Mar 18–20, 2024 · $83K · 3,000 shares Behind typical Mar 31, 2024 $28.60 → Sep 30, 2024 $19.37 · −32.3% (typical stock +3.2%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.